Lesinurad (Zurampic®)

Assessment Status Assessment process complete
Drug Lesinurad
Brand Zurampic®
Indication For the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.
Assessment Process
Rapid review commissioned 15/03/2017
Rapid review completed 20/03/2017
Rapid review outcome Full Pharmacoeconomic Assessment Not Recommended
Full pharmacoeconomic assessment commissioned by HSE 29/03/2017
Pre-submission consultation with Applicant 22/05/2017
Full submission received from Applicant 07/06/2018
Preliminary review sent to Applicant 18/07/2018
NCPE assessment re-commenced 15/08/2018
Factual accuracy sent to Applicant 15/11/2018
NCPE assessment re-commenced 21/11/2018
NCPE assessment completed 06/12/2018
NCPE assessment outcome The NCPE recommends that lesinurad not be considered for reimbursement*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary